This Virtual Education Program, provided by the iCMLf in partnership with The Max Foundation, offers a series of webcast presentations from leading hematologists.

These presentations provide updated information on treatment advances and best practice management of CML, including disease monitoring and new therapies. The sessions specifically address issues of CML care in countries with limited access to monitoring and supplemental treatments.

The iCMLf Virtual Education Program is supported by an unrestricted educational grant from Novartis Oncology.

Modules des langues  français

Módulos en español

The Importance of Molecular Monitoring in CML

Susan Branford, Australia 

• Measurement of BCR-ABL transcript levels to assess residual disease
• Recommended monitoring for CML
• The significance of achieving a major molecular response

The importance of BCR-ABL kinase domain mutation analysis in CML

  Susan Branford, Australia

• Mutations as a mechanism of imatinib resistance
• Why mutations arise
• When to test for mutations
• Therapeutic options in the presence of mutations

Transplantation for CML in 2011: Who, why, when?

Jerry Radich, Seattle, USA

• Definition of optimal response to imatinib
• Managing suboptimal response, case study
• Adherence and molecular response
• Role of mutations, criteria for mutation screening on 1st line therapy
• Dose related toxicities with TKI’s; concomitant medications

CML Treatment with imatinib

John Goldman, London, UK

• Biology and mechanisms of CML
• Mechanism of action of imatinib
• Results of the IRIS study
• Adverse effects of imatinib
• Methods to detect residual disease
• Imatinib in children and in pregnancy

European LeukemiaNet (ELN) recommendations 2009

Michele Baccarani, Bologna, Italy

• Predicting response to imatinib
• Depth of response, does it matter?
• Primary and secondary failure to imatinib
• How to monitor response
• Treatment recommendations

Optimising Response and Managing Resistance to Treatment

Tim Hughes, Adelaide, Australia

• Definition of optimal response to imatinib
• Suboptimal response
• Considerations for managing suboptimal response, case study
• Adherence and molecular response
• Role of mutations, criteria for mutation screening on first line therapy
• Dose related toxicities with TKI’s; concomitant medications

Treatment of patients after first line therapy

Jorge Cortes, Houston, USA

• Survival post imatinib
• Treatment with second generation TKIs (2nd line and 1st line)
• Optimal time to switch therapy
• Strategies to prevent imatinib failure
• Role of interferon and transplantation
• Presentation of new agents under investigation

Practical recommendations for
the management of CML patients:

Interview with Prof. Timothy Hughes

conducted by Pat Garcia-Gonzalez, Executive Director of The Max Foundation